Abstract
Because of its complex pathogenesis, chronicity, and high rates of recurrence, melasma is regarded as a challenging skin disorder. Topical treatments are often offered as first-line therapy. However, many patients are unaware that melasma is recurrent and requires long-term management. Hydroquinone is effective for controlling relapses and has become the standard of care for melasma in many countries. Nonetheless, it is limited by its side effect profile. Certain patient profiles who have had prior therapy and/or are refractory to treatment may be offered an alternative, that is topical tranexamic acid (TXA) alone or in combination with other modalities.This review provides a summary of current evidence on topicalTXA as aDo treatment Not Copy for certain case profiles.This paper aims to fill knowledge gaps in terms of currently available options, highlighting the role of Penalties topicalTXAApply alone or in combination with other active ingredients (ie, topical TXA 2% with patented delivery technology).
Original language | English (US) |
---|---|
Pages (from-to) | 386-392 |
Number of pages | 7 |
Journal | Journal of Drugs in Dermatology |
Volume | 22 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2023 |
ASJC Scopus subject areas
- General Medicine